Cargando…

Small dose rate changes significantly affect the magnitude of cellular signaling in response to high LET exposure

Purpose: The purpose of this study was to determine whether small differences in dose rate influence cellular response following radiation exposure. Introduction: Astronauts will receive chronic low-dose exposure to charged particles during space travel. The heterogeneous mix of energetic heavy ions...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sridharan, D.M., Roppel, R.D., Chan, R., Wilson, W.C., Whalen, M.K., Chappell, L.J., Pluth, J.M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2014
Materias:	Oral NASA Session
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3941518/ http://dx.doi.org/10.1093/jrr/rrt203

Ejemplares similares

Neuronal stress following exposure to (56)Fe particles and the effects of antioxidant-rich diets
por: Poulose, Shibu M., et al.
Publicado: (2014)

Genotoxicity of charged particles of importance in space flight using murine kidney epithelial cells
por: Kronenberg, Amy, et al.
Publicado: (2014)

S116: CELLULAR AND MOLECULAR MECHANISMS OF EVI1-EXPRESSING MLL-REARRANGED ACUTE MYELOID LEUKEMIA
por: Châtel-Soulet, Hugues-Etienne, et al.
Publicado: (2022)

S289: PPP1R1B BINDS IRON REGULATORY PROTEINS AND MODULATES IRON CELLULAR CONTENT
por: Calvo López, Laura, et al.
Publicado: (2023)

S255: CELLULAR SENESCENCE AND INFLAMMATORY PROGRAMS ARE UNINTENDED CONSEQUENCES OF CRISPR-CAS9 GENE EDITING IN HEMATOPOIETIC STEM AND PROGENITOR CELLS
por: Conti, Anastasia, et al.
Publicado: (2023)

S132: TOLERABILITY AND EFFICACY OF THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY MAGROLIMAB COMBINED WITH AZACITIDINE IN FRONTLINE PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA: PHASE 1B RESULTS
por: Daver, N. G., et al.
Publicado: (2022)

WS05.04 SARS-CoV-2 infection is reduced in both immortalised and primary CFTR-modulated human bronchial epithelial cells
por: Lotti, V., et al.
Publicado: (2022)

S130: NPM1 MUTATED AML: IMPACT OF CO-MUTATIONAL PATTERNS - RESULTS OF THE EUROPEAN HARMONY ALLIANCE
por: Hernández-Sánchez, A., et al.
Publicado: (2022)

S129: TAKEAIM LEUKEMIA- A PHASE 1/2A STUDY OF THE IRAK4 INHIBITOR EMAVUSERTIB (CA-4948) AS MONOTHERAPY OR IN COMBINATION WITH AZACITIDINE OR VENETOCLAX IN RELAPSED/REFRACTORY AML OR MDS
por: Garcia-Manero, G., et al.
Publicado: (2022)

S237: ORCA-T, AN ENGINEERED ALLOGRAFT, RESULTS IN HIGH GVHD-FREE AND RELAPSE-FREE SURVIVAL FOLLOWING MYELOABLATIVE CONDITIONING FOR HEMATOLOGICAL MALIGNANCIES
por: Meyer, E., et al.
Publicado: (2022)

WS21.01 AQP5 and CFTR, two genes associated with pseudo-aquagenic palmoplantar keratoderma?
por: Girodon, E., et al.
Publicado: (2022)

Chromosomal aberrations in human lymphocytes and fibroblasts after exposure to very low doses of high-LET radiation
por: Hada, Megumi, et al.
Publicado: (2014)

Increased Artemis levels confer radioresistance to both high and low LET radiation exposures
por: Sridharan, Deepa M, et al.
Publicado: (2012)

S124: PHOSPHOPROTEOMICS ACCURATELY PREDICTS RESPONSES TO MIDOSTAURIN PLUS CHEMOTHERAPY IN TWO INDEPENDENT COHORTS OF FLT3 MUTANT-POSITIVE ACUTE MYELOID LEUKAEMIA
por: Dokal, Arran, et al.
Publicado: (2023)

WS21.03 Low-cost chain termination DNA sequencing PCR reaction to diagnose CFTR gene mutations
por: Ghani, M.U., et al.
Publicado: (2022)

S171: HIGHER MDMX EXPRESSION WAS ASSOCIATED WITH HYPOMETHYLATING AGENT RESISTANCE AND WORSE SURVIVAL IN MYELODYSPLASTIC SYNDROME PATIENTS, INFERRING IT A POTENTIAL THERAPEUTIC TARGET
por: Wang, Yu-Hung, et al.
Publicado: (2023)

Infections inhabituelles
Publicado: (2011)

Grippe A (H1N1) en réanimation
Publicado: (2010)

ECMO veinoveineuse
Publicado: (2013)

S273: LONG-TERM ERYTHROID RESPONSE DATA FROM PATIENTS (PTS) WITH NON-TRANSFUSION-DEPENDENT ΒETA-THALASSEMIA (NTDT) RECEIVING LUSPATERCEPT IN THE BEYOND TRIAL
por: Taher, Ali T., et al.
Publicado: (2023)

S127: DELTATP73 IMPOSES TP53 MUTANT-LIKE PHENOTYPES INCLUDING DRUG RESISTANCE AND POOR PROGNOSIS ON TP53-WILD TYPE ACUTE MYELOID LEUKEMIA.
por: Pereira-Martins, Diego A, et al.
Publicado: (2023)

S131: CLINICAL IMPLICATIONS OF SECONDARY-AML TYPE MUTATIONS IN PATIENTS WITH DE NOVO ACUTE MYELOID LEUKEMIA
por: Sun, K., et al.
Publicado: (2022)

WS20.06 Co-infection with Nocardia farcinia and SARS-CoV-2 causing the death of an adolescent with cystic fibrosis
por: Chapman, J., et al.
Publicado: (2022)

S142: FOXO1-RICTOR AXIS INDUCES ADAPTIVE INCREASE IN AKT ACTIVITY DURING BCR INHIBITOR THERAPY IN CLL: IMPLICATIONS FOR COMBINATION THERAPY
por: Ondrisova, Laura, et al.
Publicado: (2023)

Determining clinical significance independently from statistical significance? Implications for practice
por: Schreiber, S, et al.
Publicado: (2012)

S283: THE NON-ANTICOAGULANT HEPARINOID COMPOUND, SEVUPARIN, STRONGLY REDUCES HEPCIDIN EXPRESSION IN CELLS, IN MICE AND IN HEALTHY VOLUNTEERS
por: Asperti, Michela, et al.
Publicado: (2023)

S109: P53 ORCHESTRATES SPATIO-TEMPORAL EPIGENOME REWIRING TO TRANSCRIPTIONALLY PREVENT MALIGNANT TRANSFORMATION
por: Serra, François, et al.
Publicado: (2023)

S234: CLINICAL-GRADE MBIL21/4-1BBL EXPANDED NK CELLS EXHIBIT STRONGER COMPETENCE COMPARED WITH PRIMARY NK CELLS AGAINST HCMV INFECTION
por: Shang, Q.-N., et al.
Publicado: (2022)

S146: GENOMIC EVOLUTION AND RESISTANCE TO PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR (CBTKI) PRE-TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS: RESULTS FROM THE PHASE I/II BRUIN STUDY
por: Brown, Jennifer R., et al.
Publicado: (2023)

S203: QUADRUPLET INDUCTION THERAPY, ASCT AND MRD-MODULATED CONSOLIDATION AND TREATMENT CESSATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA: FINAL ANALYSIS OF THE MASTER TRIAL
por: Costa, Luciano, et al.
Publicado: (2023)

S219: PREDICTING THROMBOTIC RISK IN PATIENTS WITH HODGKIN LYMPHOMA: A MULTICENTRIC STUDY OF THROLY AND KHORANA RISK SCORES
por: Assanto, Giovanni Manfredi, et al.
Publicado: (2023)

S193: BMS-986393 (CC-95266), A G PROTEIN–COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D (GPRC5D)–TARGETED CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM A PHASE 1 STUDY
por: Bal, Susan, et al.
Publicado: (2023)

S266: DIFFERENT MOLECULAR VASO-OCCLUSIVE TRIGGERS STIMULATE DISTINCT VASO-OCCLUSIVE PROFILES: IN VIVO RESULTS FROM MICE WITH SICKLE CELL ANEMIA
por: Gushiken, Lucas F. S., et al.
Publicado: (2023)

S302: LONG-TERM SAFETY AND EFFICACY OF EFGARTIGIMOD IN PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA: INTERIM RESULTS OF THE ADVANCE+ STUDY
por: Carpenedo, Monica, et al.
Publicado: (2023)

Let's talk about rings
por: Rarey, Matthias, et al.
Publicado: (2013)

S202: CARTITUDE-1 FINAL RESULTS: PHASE 1B/2 STUDY OF CILTACABTAGENE AUTOLEUCEL IN HEAVILY PRETREATED PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Munshi, Nikhil, et al.
Publicado: (2023)

S125: NON-GENETIC RESISTANCE TO MENIN INHIBITION IN AML IS REVERSIBLE BY PERTURBATION OF KAT6A
por: Perner, Florian, et al.
Publicado: (2023)

S268: INTERIM ANALYSIS OF A PHASE 2 TRIAL TO ASSESS THE EFFICACY AND SAFETY OF CRIZANLIZUMAB IN SICKLE CELL DISEASE PATIENTS WITH PRIAPISM (SPARTAN)
por: Anderson, Alan, et al.
Publicado: (2023)

S306: HYPERCOAGULABILITY BIOMARKERS AND THROMBIN GENERATION (TG) PREDICT VENOUS THROMBOEMBOLISM (VTE) IN METASTATIC LUNG CANCER PATIENTS
por: Gomez Rosas, Patricia, et al.
Publicado: (2023)

S168: PELABRESIB (CPI-0610) MONOTHERAPY IN PATIENTS WITH HIGH-RISK ESSENTIAL THROMBOCYTHEMIA REFRACTORY OR INTOLERANT TO HYDROXYUREA: PRELIMINARY RESULTS FROM MANIFEST STUDY
por: Passamonti, Francesco, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_felu6snmjreavq9cpl7n31d6e1